SCHEMBL3059008

SCHEMBL3059008

Nc1ccc(C(=O)O)c(S(=O)(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.61
TDP1 Q9NUW8 7/20 0.61
HSD17B10 Q99714 5/20 0.61
CASP1 P29466 3/20 0.61
CASP7 P55210 2/20 0.61
KDM4E B2RXH2 6/20 0.55
MAPT P10636 5/20 0.55
GAA P10253 3/20 0.55
CYP3A4 P08684 3/20 0.55
ESR2 Q92731 1/20 0.55
PTPN1 P18031 1/20 0.55
RECQL P46063 5/20 0.50
POLB P06746 4/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
THRB P10828 3/20 0.50
HPGD P15428 3/20 0.50
APEX1 P27695 2/20 0.50
CASP6 P55212 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1373524 1.00 ALDH1A1 (0.61) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL21834461 0.98 ALDH1A1 (0.59) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL27509312 0.86 RAPGEF4 (0.50) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL16369640 0.86 ALDH1A1 (0.62) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL8000414 0.86 RAPGEF4 (0.50) ALDH1A1TDP1HSD17B10CASP1CASP7
Water SCHEMBL28296857 0.85 RAPGEF4 (0.49) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL7420462 0.85 ALDH1A1 (0.61) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL3657583 0.84 ALDH1A1 (0.55) ALDH1A1TDP1HSD17B10CASP1CASP7
SCHEMBL8519995 0.83 ALDH1A1 (0.53) ALDH1A1TDP1HSD17B10CASP1CASP7
Potassium Ion SCHEMBL28557203 0.81 ALDH1A1 (0.52) ALDH1A1TDP1HSD17B10CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4445553-B2 2010-04-07 JP claimed
US-7632591-B2 Branched multiblock polybenzimidazole-benzamide copolymer and method for preparing the same, electrolyte membrane and paste/gel prepared therefrom LG CHEM, LTD. (KR) 2009-12-15 US claimed
JP-2008512561-A 2008-04-24 JP claimed
WO-2007055459-A1 BRANCHED MULTIBLOCK POLYBENZIMIDAZOLE-BENZAMIDE COPOLYMER AND METHOD FOR PREPARING THE SAME, ELECTROLYTE MEMBRANE AND PASTE/GEL PREPARED THEREFROM LG CHEM, LTD. (KR) 2007-05-18 WO claimed
US-20070111075-A1 Branched multiblock polybenzimidazole-benzamide copolymer and method for preparing the same, electrolyte membrane and paste/gel prepared therefrom LG CHEM, LTD. (KR) 2007-05-17 US claimed
EP-0572560-B1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 2003-01-29 EP claimed
EP-0712866-B1 Polymer scale deposition preventive agent SHINETSU CHEMICAL CO (JP) 1998-07-29 EP claimed
EP-0572560-A4 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. SHAPIRO HOWARD K (US) 1995-04-26 EP claimed
EP-0572560-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1993-12-08 EP claimed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO claimed
EP-0261079-B1 REACTIVE DYES, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1991-10-16 EP claimed
CN-111712263-B Maytansinoids-based drug delivery systems 拉德克斯公司 2024-12-17 CN disclosed
CN-118852324-A Albumin binding products of auristatin E derivatives 拉德克斯公司 2024-10-29 CN disclosed
US-12043593-B2 Method for preparation of potassium 5-lodo-2-carboxybenzene sulfonate ARXADA AG (CH) 2024-07-23 US disclosed
US-12043593-B2 Method for preparation of potassium 5-lodo-2-carboxybenzene sulfonate ARXADA AG (CH) 2024-07-23 US disclosed
EP-0036838-A2 Azo dyestuffs, their preparation and their use CIBA-GEIGY AG (CH) 1981-09-30 EP disclosed
US-4283331-A FIBER-REACTIVE DYES CIBA-GEIGY CORPORATION (US) 1981-08-11 US disclosed
US-4270918-A METALLIZED TRIAZINE-FUNCTIONAL MONOAZO DYE CIBA-GEIGY CORPORATION (US) 1981-06-02 US disclosed
US-4138558-A Anthraquinone compounds NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1979-02-06 US disclosed
US-4113720-A Disperse azo dye with diaminopyrimidine coupling component BASF AKTIENGESELLSCHAFT (DE) 1978-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043593-B2 Method for preparation of potassium 5-lodo-2-carboxybenzene sulfonate KCNK5, KCNJ2, KCNB1 ALDH1A1 1352/4885TDP1 4164/4885HSD17B10 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.